Clinical Efficacy Evaluation of Supraglottic Airway Device SafeLM™ in Paediatric Population
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: SafeLM™ as the airway management device during general anaesthesia.
- Кому может быть актуально
- Состояния в реестре: Anesthesia, Supraglottic Airway Efficiency, Paediatric Airway Management. Базовые параметры: 0 лет — 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Малайзия
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
The goal of this interventional study is to evaluate the clinical efficacy of SafeLM™, a video laryngeal mask airway device in paediatric population. The main questions it aims to answer are: 1. To determine the success rate, ease of device insertion, time for insertion, and how well the device seals the airway by measuring the oropharyngeal leak pressure (OPLP) of SafeLM™. 2. To determine the incidence of complication associated with SafeLM™ usage. 3. To study the association of glottic view with success rate and rate of complication. Participants perioperative clinical data will be collected for data analysis.
Подробное описание
Paediatric patients who are scheduled for surgery where supraglottic airway is deemed appropriate will be recruited with written consent. Following preoxygenation, application of standard monitors, and induction of general anaesthesia, an appropriate size of SafeLM™ will be inserted according to manufacturer's recommendation. Cuff will be deflated and flattened prior, with the back of laryngeal mask lubricated. The device will be advanced by sliding the laryngeal mask down the palatopharyngeal curve along the midline in the mouth until the end of the mask reach the hypopharynx cavity and resistance is met, with the process visualised in real time through the video camera. If there is malalignment, correction manoeuvre such as jaw trust, head reposition, or mask redirection will be done. Once the distal end of mask reaches the hypopharyngeal cavity, the cuff is inflated with the recommended volume of air according to the manufacturer recommendation, until adequate cuff seal is achieved. Then, the patient is put on either spontaneous or pressure-controlled mechanical ventilation. Successful placement will be confirmed. If insertion difficulty is encountered and the laryngeal mask is required to be taken out from the oral cavity, insertion can be reattempt with the same or different size of SafeLM™ after adequate preoxygenation, and it will be considered as second attempt. If it remains unsuccessful on the 3rd attempt, SafeLM™ insertion will be abandoned, subsequent management will be decided by the attending anaesthetist. Glottic exposure grades at the end of each attempt is recorded. The time for insertion is measured for each attempt, using a stopwatch, by obtaining the duration in between the moment when the anaesthetist starts holding the SafeLM™ device, until the appearance of 2 complete continuous capnography waveform on the monitor. Following successful SafeLM™ insertion, the camera can be removed, and orogastric tube will be inserted via the gastric port only if there is clinical indication. Subsequently, oropharyngeal leak pressure (OPLP) is measured and recorded by dialing the fresh gas flow rate to 3 L/min and putting the adjusting pressure limiting (APL) valve at 40 cmH2O, in manual ventilation mode. The equilibrium pressure that the pressure gauze pointer settles down at is the OPLP. The anaesthesia is maintained using TIVA or volatile agent as per the anaesthetist's discretion, keeping the MAC at least 1.0 or BIS level at 40-60, whichever is applicable. All the patients will receive IV dexamethasone 0.2 mg/kg and IV granisetron 0.02 mg/kg as post operative nausea vomiting (PONV) prophylaxis. At the end of anaesthesia, anaesthetic agent administration is terminated. If non-depolarising neuromuscular blockade is given during anaesthesia, an appropriate dose of reversal agent will be given according to the depth of neuromuscular blockade based on either clinical signs or nerve stimulation examination, whichever applicable. After the adequate neuromuscular blockade reversal is confirmed, the laryngeal mask can be removed at the awake state or deep plane of anaesthesia. Patient will be monitored in the post-anaesthesia care unit for at least 30 minutes prior sending back to the designated ward for continuation of care.
Вмешательства
- Устройство SafeLM™ as the airway management device during general anaesthesia
Appropriate size of SafeLM™ is selected for participants as manufacturer recommendation. Size 2 is for participants with body weight of 10-20 kg, recommended cuff volume to be inflated is 10 to 15 ml. Size 2.5 is for participants with body weight of 20-30 kg, recommended cuff volume to be inflated is 14 to 21 ml. Size 3 is for participants with body weight of 30-50 kg, recommended cuff volume to be inflated is 20 to 30 ml. Size 4 is for participants with body weight of 50-70 kg, recommended
Первичные конечные точки
- Success rate of device placement in percentage [Срок оценки: Perioperative]
- Oropharyngeal leak pressure (OPLP) in cmH2O [Срок оценки: From the time of successful device placement confirmation to the time of determination of OPLP before commencement of surgery]
- Glottic exposure grades [Срок оценки: At the time of completion of device placement procedure, when the distal end of the cuff reaches the hypopharyngeal cavity, resistance is met, and the cuff is inflated with appropriate volume of air as per manufacturer recommendation.]
Вторичные конечные точки (12)
- Insertion time in seconds (s) [Срок оценки: Periprocedural]
- The ease of SafeLM™ insertion [Срок оценки: Perioperative]
- Anaesthetists' overall satisfactory score [Срок оценки: Perioperative]
- Rate of intraoperative laryngospasm [Срок оценки: Intraoperative]
- Rate of intraoperative bronchospasm [Срок оценки: Intraoperative]
- Rate of intraoperative desaturation event [Срок оценки: Intraoperative]
- Rate of intraoperative gastric aspiration event [Срок оценки: Intraoperative]
- Rate of post-extubation gastric aspiration event [Срок оценки: Perioperative]
- Rate of post-extubation sore throat event [Срок оценки: Perioperative]
- Rate of post-extubation finding of blood stain [Срок оценки: Perioperative]
- Rate of post-extubation laryngospasm [Срок оценки: Perioperative]
- Rate of post-extubation bronchospasm [Срок оценки: Perioperative]
Критерии участия
Критерии включения
- Patients who are scheduled for a surgery under general anaesthesia where supraglottic airway is deemed appropriate.
- ASA I or II
- Age up to 18 years old
- Body weight of 10 kg and above
Критерии исключения
- Presence of risk of gastric regurgitation or aspiration
- Recent upper respiratory tract infection within 2 weeks
- Uncontrolled respiratory co-morbidity such as bronchial asthma, chronic lung disease, restrictive lung disease
- Presence of congenital airway abnormalities
- Patient or next of kins refusal in participating this study
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Да
Дизайн исследования
- Распределение
- Не применимо
- Модель
- Одна группа
- Маскирование
- Открытое
- Основная цель
- Другое
Центры проведения
Малайзия · 2 центра
- Universiti Kebangsaan Malaysia — Cheras
- University of Malaya — Kuala Lumpur
Идентификаторы
NCT: NCT07266389 · JEPUKM-JEP-2025-255